Natera executives said Signatera—its blood‑based minimal residual disease (MRD) assay—delivered record growth in Q4 2025 and will be enhanced with phased and structural variant tracking in a new version due clinically in late spring or early summer 2026. The company highlighted expanding Medicare reimbursement prospects and data generation plans to support broader indications. CEO Steve Chapman outlined a roadmap combining ctDNA data with digital pathology and tumor sequencing to create a multimodal MRD model, with phased rollouts scheduled for mid‑2026. Natera expects improved average selling prices (ASPs) tied to expanded Medicare coverage and additional cancer types. The company is investing heavily in data generation and algorithmic enhancements to increase sensitivity and clinical utility of MRD for therapy monitoring and adjuvant settings.